RESEARCH ARTICLE

VALUE OF ADMISSION GLYCOLYTED HEMOGLOBIN LEVEL IN PATIENTS WITH ACUTE ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION.

Riham Elfawal¹, Zizi Saadi² and Amal Kandil³.

1. Clinical Pathology Department, Faculty of Medicine, Alexandria University/Basic Medical Science Department, Al Farabi Medical College.
2. Cardiology Department, Faculty of Medicine, Zagazig University, Egypt.
3. Medical Surgical Department, Faculty of Nursing, Alexandria University, Egypt Nursing Department, Al Farabi Faculty of Dentistry and Nursing.

Abstract

Introduction: -
Stress hyperglycemia in STEMI patients was associated with significantly increased rates of mortality and congestive heart failure and shock. Most of these studies, however were in trials of fibrinolytic therapy, conversely the evidence linking hyperglycemia with an adverse prognosis in patients treated with primary percutaneous coronary intervention (PCI) is limited and derived mainly from observational registries (Planner et al., 2013).

In AMI, stress hyperglycemia commonly occurs secondary to increased catecholamine levels, due to stress hyperglycemia so, looking only at plasma glucose levels at the time of an AMI can’t predict the prognosis. (Cakmak et al., 2008).

Glycosylated hemoglobin (HbA1c) beyond its role in diagnosis of diabetes mellitus, it is a marker of long-term glycemic control and elevated HbA1c is associated with an increased risk of cardiovascular diseases in patients with diabetes, HbA1c is also associated with all cause mortality and cardiovascular disease even in absence of diabetes (Nafto et al., 2013).

Aim of the work
Our study aimed to assess predictive value of HbA1c level in patients presented to Zagazig university hospital by acute STEMI treated either with thrombolytic therapy or primary angioplasty, on shortterm outcome of adverse cardiac events and outcome of PCI.

Patients and method
The study included 60 patients with Acute STEMI patient’s candidate for reperfusion therapy admitted in cardiology department Zagazig university hospital in 2013.

Corresponding Author:- Riham Elfawal.
Address:- Clinical Pathology Department, Faculty of Medicine, Alexandria University/Basic Medical Science Department, Al Farabi Medical College.
Inclusion criteria:
Acute STEMI, patients with clinical presentation of STEMI within 12 h of symptom onset and with persistent ST-segment elevation or new or presumed new LBBB, early mechanical 1ry PCI or pharmacological reperfusion should be performed as early as possible. Patients were classified into 3 groups according to HbA1c level
2. Group (2): HbA1c level 6.5 to 8.5 (possibly diabetic)

Exclusion criteria:
1. Passed time MI (If patients presented by symptoms more than 24hours).
2. Patients who have undergone rescue PCI.
3. Patients who have contraindication to dye as dye allergy, renal failure.
4. Patients presented by NSTEMI or unstable angina.
5. Patients who have contraindication to dye as dye allergy, renal failure.
6. Red cell turnover, such as congenital or acquired haemolysis, chronic malaria, severe iron deficiency anaemia, recent blood donation and major blood loss (after surgery), will lead to spurious HbA1c level.
7. Concomitant use of many drugs to treat patients with malignancies, HIV or hepatitis C virus infection, may have a glycated hemoglobin-lowering effect.
8. Alcoholism, supplementation with vitamins C and E, erythropoietin treatment, and chronic ingestion of salicylates, is also known to reduce the level of HbA1c.
9. Vitamin B12 or folate deficiency, make HbA1c higher level than expected.

All patients then were subjected to:
Full history taking:
1. Demographic data including age, sex.
2. Detailed medical and cardiac history including:
3. Diagnosis of acute MI was done on the basis of: at least two of the following
4. Typical chest pain > 20 minute, or atypical chest pain with suggestion of acute coronary syndrome.
5. ECG finding as (ST segment elevation > 2mm in two contiguous precordial leads or ST segment elevation ≥ 1mm in two contiguous limb leads, hyper acute T wave or new onset LBBB with ischemic evidence.
6. Positive Cardiac enzymes and troponin.
7. History of ischemic heart disease.
8. Through physical examination including:
9. Resting 12 lead electrocardiography, Cardiac enzymes, and Blood sugar measurement:
10. Patient is diagnosed to be diabetic when:
11. History of diabetes, either type 1 or type 2.
12. FBG ≥126 mg/dl (7.0 mmol/l).
13. 2-h postprandial glucose ≥200 mg/dl (11.1 mmol/l)
14. In a patient with classic symptoms of hyperglycemia or hyperglycemic crisis a random plasma glucose ≥200 mg/dl (11.1 mmol/l) (ADA 2010).

HbA1c measurement:
Blood sample was taken within 24h from admission
HbA1c cut off point for diagnosis of diabetes is ≥ 6.5% (48 mmol/mol), the test was performed in a laboratory using a method that is National Glycohemoglobin Standardization Program (NGSP). Diagnosis should be confirmed with a repeat HbA1c test, unless clinical symptoms and plasma glucose levels >200mg/dl are present (ADA, 2010).

Angiography:
1. Invasive intervention was done either at admission by (1ry PCI) or CA was done within month (3-28 days) from taking thrombolytic therapy in stable asymptomatic patients (Hochman et al., 2006).
2. 45 cases where subjected to (1ry PCI) and 15 cases received thrombolytic, then coronary angiography were done within one month in patients received thrombolytic therapy.
3. For primary PCI wiring culprit artery based upon ECG, revascularization of culprit artery only was done unless patient in cardiogenic skoch (Wigins et al., 2010).

4. We use the visual method for evaluation and assessment of number of significant diseased coronary arteries, with special focus on infacted related artery (guided by ECG) on type of the lesion either type A, B, C (Ryan et al;1988)

5. Also, we used TIMI flow grading system in primary PCI cases

**Follow up period:**
Was done six months after the onset of MI mainly for:
1. Heart failure according to Killip class classification.
2. Reinfarction.
5. Ventricular tachyarrhythias.

Through phone calls followed by hospital visit in outpatient clinic

**Statistical analysis**
Statistical presentation and analysis of the present study was conducted, using the mean, standard deviation, analysis of variance [ANOVA] test and chi-square test by SPSS V 21, students "t" test was used to test the significance of the difference between two independent sample means, value of < 0.05 indicates a significant result.

**Results:**

**Demographic data:**
there was no significant difference between the three groups regarding age, sex, hypertension, smoking, family history and obesity, previous MI, previous PCI (p value > 0.05).

**Table 1:** Shows demographic data in the study groups (1,2&3) according to HbA1c

<table>
<thead>
<tr>
<th>I. VARIABLE</th>
<th>Group (1) (n=27)</th>
<th>A. Group (2) (n=17)</th>
<th>B. Group(3)No (n=16)</th>
<th>C. P-Value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>X ±SD</td>
<td>X ±SD</td>
<td>X ±SD</td>
<td></td>
</tr>
<tr>
<td>D. Age</td>
<td>57.9±10.2</td>
<td>58.3±7.1</td>
<td>57.3±8.5</td>
<td>0.94</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Gender</th>
<th>N</th>
<th>%</th>
<th>N</th>
<th>%</th>
<th>N</th>
<th>%</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Female</td>
<td>4</td>
<td>14.8%</td>
<td>4</td>
<td>23.9%</td>
<td>4</td>
<td>25%</td>
<td>0.67 N.sig</td>
</tr>
<tr>
<td>Male</td>
<td>23</td>
<td>85.2%</td>
<td>13</td>
<td>76.5%</td>
<td>12</td>
<td>75%</td>
<td></td>
</tr>
<tr>
<td>HTN</td>
<td>13</td>
<td>48.1%</td>
<td>8</td>
<td>47.1%</td>
<td>11</td>
<td>68.8%</td>
<td>0.35 N.sig</td>
</tr>
<tr>
<td>Smoker</td>
<td>15</td>
<td>55.6%</td>
<td>8</td>
<td>47.1%</td>
<td>6</td>
<td>37.5%</td>
<td>0.51 N.sig</td>
</tr>
<tr>
<td>Family history</td>
<td>3</td>
<td>11.1%</td>
<td>0</td>
<td>0%</td>
<td>3</td>
<td>18.8%</td>
<td>0.19 N.sig</td>
</tr>
<tr>
<td>Obesity</td>
<td>2</td>
<td>7.4%</td>
<td>2</td>
<td>11.8%</td>
<td>2</td>
<td>12.5%</td>
<td>0.83 N.sig</td>
</tr>
<tr>
<td>Previous MI</td>
<td>0</td>
<td>0%</td>
<td>2</td>
<td>11.8%</td>
<td>3</td>
<td>18.8%</td>
<td>0.083 N.sig</td>
</tr>
<tr>
<td>Previous PCI</td>
<td>0</td>
<td>0%</td>
<td>1</td>
<td>5.8%</td>
<td>2</td>
<td>12.5%</td>
<td>0.06 N.sig</td>
</tr>
</tbody>
</table>
Table 2: Show number and % patients who had undergone 1ry PCI or received thrombolytic therapy in the study groups (1,2&3) according to HbA1C

<table>
<thead>
<tr>
<th>II. VARIABLE</th>
<th>Group (1) (n=27)</th>
<th>A. Group (n=17)</th>
<th>(2)</th>
<th>B. Group(3)No (n=16)</th>
<th>C. P-Value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>X ±SD</td>
<td>X ±SD</td>
<td>X ±SD</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>N   %</td>
<td>N   %</td>
<td>N   %</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1ry PCI</td>
<td>18 66.6%</td>
<td>17 100%</td>
<td>10 62.5%</td>
<td>0.05 N.sig</td>
<td></td>
</tr>
<tr>
<td>Thrombolytic therapy</td>
<td>9 33.3%</td>
<td>0 0%</td>
<td>6 37.5%</td>
<td>0.78 N.sig</td>
<td></td>
</tr>
</tbody>
</table>

There was no statistically significant difference between three groups regarding type of reperfusion (p value>0.05).

Number of diseased vessels

Group 1:-
20 patients (74.1%) have single vessel disease, 4 patients (14.8%) have two vessel disease, 3 patients (11.1%) have three vessel disease.

Group 2:-
13 patients (76.4%) have single vessel disease, 2 patients (11.8%) have two vessel disease and 2 patients 11.8% have three vessel disease.

Group 3:-
1 patient (6.2%) has single vessel disease, 6 patients (37.5%) had two vessel disease and 9 patients (56.3%) have three vessel disease.

Regarding single vessel disease there was high statistically significant difference between the three groups (p value <0.001).

Regarding three vessel disease there was high statistically significant difference between the three group (p value <0.001).

Table 3: Show number of diseased vessels in the study groups (1,2&3)

<table>
<thead>
<tr>
<th>Variable</th>
<th>Group (1) n= 27</th>
<th>Group (2) n= 17</th>
<th>Group (3) n=16</th>
<th>Sig</th>
</tr>
</thead>
<tbody>
<tr>
<td>Single vessel disease</td>
<td>20 (74.1%)</td>
<td>13 (76.4%)</td>
<td>1 (6.2%)</td>
<td>0.000</td>
</tr>
<tr>
<td>Two vessel disease</td>
<td>4 (14.8%)</td>
<td>2 (11.8%)</td>
<td>6 (37.5%)</td>
<td>0.12</td>
</tr>
<tr>
<td>Three vessel disease</td>
<td>3 (11.1%)</td>
<td>2 (11.8%)</td>
<td>9 (56.3%)</td>
<td>0.001</td>
</tr>
</tbody>
</table>
Lesion type in the study group (1,2&3) according HbA1c

**Group 1:**
19 patients (70.4%) have type A lesion, 5 patients (18.5%) have type B lesion and 3 patients (11.1%) had type C lesion.

**Group 2:**
6 patients (35.3%) have type A lesion, 9 patients (52.9%) have type B lesion and 2 patients (11.8%) have type C lesion.

**Group 3:**
3 patients (18.8%) had type A lesion, 3 patients (18.8%) have type B lesion and 10 patients (62.5%) had type C lesion.

There was high statistically significant difference between the three groups regarding lesion type A, B and C p value (0.000)

**Table 4:** -shows lesion type in relation to the study groups according to HbA1c

<table>
<thead>
<tr>
<th>Lesion type</th>
<th>Group (1) n= 27</th>
<th>Group (2) n= 17</th>
<th>Group (3) n=16</th>
<th>Sig</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>19 (70.4%)</td>
<td>6(35.3%)</td>
<td>3(18.8%)</td>
<td>0.000</td>
</tr>
<tr>
<td>B</td>
<td>5(18.5%)</td>
<td>9(52.9%)</td>
<td>3(18.8)</td>
<td>High. sig</td>
</tr>
<tr>
<td>C</td>
<td>3(11.1%)</td>
<td>2(11.8%)</td>
<td>10(62.5%)</td>
<td></td>
</tr>
</tbody>
</table>
TIMI flow in patients who had undergone primary PCI:

Table 5: shows TIMI flow grade in primary PCI cases (n=45)

<table>
<thead>
<tr>
<th>Group</th>
<th>Patients undergone primary PCI in each group of HbA1C</th>
<th>TIMI 0</th>
<th>TIMI 1</th>
<th>TIMI 2</th>
<th>TIMI 3</th>
<th>Sig</th>
</tr>
</thead>
<tbody>
<tr>
<td>Group (1) = 18</td>
<td>3 (16.7%)</td>
<td>3 (16.7%)</td>
<td>3 (16.7%)</td>
<td>9 (50%)</td>
<td>0.04</td>
<td></td>
</tr>
<tr>
<td>Group (2) = 17</td>
<td>1 (5.9%)</td>
<td>2 (11.8%)</td>
<td>6 (35.5)</td>
<td>8 (47.1%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Group (3) = 10</td>
<td>1 (10%)</td>
<td>6 (60%)</td>
<td>1 (10%)</td>
<td>2 (20%)</td>
<td>Sig</td>
<td></td>
</tr>
</tbody>
</table>

There was statistically significant difference between the three groups regarding TIMI flow value < 0.05.
Table 6: shows groups (1, 3) cross tabulation with TIMI 1:

<table>
<thead>
<tr>
<th>Groups</th>
<th>TIMI1</th>
<th>Total</th>
<th>Sig</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>NO</td>
<td>YES</td>
<td></td>
</tr>
<tr>
<td>1.00</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Count</td>
<td>15</td>
<td>3</td>
<td>18</td>
</tr>
<tr>
<td>% within group</td>
<td>83.3%</td>
<td>16.7%</td>
<td>100.0%</td>
</tr>
<tr>
<td>3.00</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Count</td>
<td>4</td>
<td>6</td>
<td>10</td>
</tr>
<tr>
<td>% within group</td>
<td>40.0%</td>
<td>60.0%</td>
<td>100.0%</td>
</tr>
<tr>
<td>Total</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Count</td>
<td>19</td>
<td>9</td>
<td>27</td>
</tr>
</tbody>
</table>

There was statistically significant difference between the group (1, 3) regarding TIMI 1, with higher percentage in favor of group 3, value <0.05

Cardiovascular events in the period of follow up in the study group (1, 2&3) according to HbA1c

Group (1):
2 patients (7.4%) suffered from reinfarction, 2 patients (7.4%) were died, 1 patient (3.7%) suffered from heart failure, 22 patients (81.5%) didn’t suffered from any events

Group (2):
1 patient (5.9%) suffered from reinfarction, 2 patients (11.8%) were died, 1 patient (5.9%) suffered from heart failure, and 13 patients (76.5%) didn’t suffer from any events

Group (3):
2 patients (12.5%) suffered from reinfarction, 6 patients (37.5%) were died, 2 patients (12.5%) suffered from heart failure, and 6 patients (37.5%) didn’t suffer from any events

There was statistically significant difference in cardiovascular events and mortality in the study group p value (<0.05).

Table 7: shows adverse cardiac events in the study groups according to HbA1c:

<table>
<thead>
<tr>
<th>Cardiac Events</th>
<th>Group (1) n= 27</th>
<th>Group (2) n= 17</th>
<th>Group (3) n=16</th>
<th>Sig</th>
</tr>
</thead>
<tbody>
<tr>
<td>Re infarction</td>
<td>2 (7.4%)</td>
<td>1 (5.9%)</td>
<td>2 (12.5%)</td>
<td>0.04 Sig</td>
</tr>
<tr>
<td>Mortality</td>
<td>2 (7.4%)</td>
<td>2 (11.8%)</td>
<td>6 (37.5%)</td>
<td></td>
</tr>
<tr>
<td>Heart failure</td>
<td>1 (3.7%)</td>
<td>1 (5.9%)</td>
<td>2 (12.5%)</td>
<td></td>
</tr>
<tr>
<td>No cardiac events</td>
<td>22 (81.5%)</td>
<td>13 (76.5%)</td>
<td>6 (37.5%)</td>
<td></td>
</tr>
</tbody>
</table>
The present study shows significant difference among different groups of HbA1c as regard the degree of successful reperfusion. This was supported by the significant difference among different groups of HbA1c as regard TIMI flow grades in patients who have undergone mechanical reperfusion with higher percentage of TIMI 3 in group (1) and the significant positive correlation between HbA1c and absent STR.

The present study shows that there was significant difference among different groups of HbA1c as regard adverse cardiac events on short term follow up period, a multi regression analysis in the present study confirmed that HbA1c over 6.5% is an independent predictor outcome of adverse cardiac events.

**Discussion**

The present study shows that in patients with acute STEMI, admission higher HbA1c level is associated with more severe CAD, lower ST-segment resolution, higher percentage of TIMI 1 flow and lower rate of complete revascularization with TIMI 3 flow after primary angioplasty and higher incidence of mortality.

Stress hyperglycemia in STEMI patients was associated with significantly increased rates of mortality and congestive heart failure and shock, most of these studies, were in trials of fibrinolysis therapy, the evidence linking hyperglycemia with an adverse prognosis in patients treated with primary percutaneous coronary intervention (PCI) derived mainly from observational registries (Planner et al., 2013)

In the present study the peak CK-MB shows statistically significant difference among different HbA1c groups with higher mean peak CK-MB in group (3) with statistically significant positive correlation between peak CK-MB and HbA1c ($r=0.771$, $p=0.00$). This goes with the fact that hyperglycemia with STEMI is associated with significantly larger enzymatic infarct size beyond the fact that the stress response with higher catecholamines, cortisol, cytokines and TNF-α lead to more extensive myocardial damage. This was concordant with (Naito et al., 2013) who found significant difference between HbA1c level and peak CK-MB

In the present study there was significant difference among different HbA1c groups as regard ST-segment resolution (STR), with higher percentage of absent STR in group (3) with statistically significant positive correlation between HbA1c and absent STR ($r=0.290$, $p=0.02$). This was concordant with (Razvi et al., 2013) who found that hyperglycemia and higher HbA1c in acute STEMI is associated with impairment in ST-segment resolution, also there is a link between hyperglycemia and inadequate tissue level myocardial reperfusion. This goes with the fact
that hyperglycemia reflect insulin deficiency which increase expression of adhesion molecules, enhance leukocyte adhesion to capillary walls and aggravate free-radical-related reperfusion injury augmenting the formation of microthrombi by increasing platelet aggregation, hyperglycemia also alter endothelium-dependent vasodilatation and impair endogenous fibrinolysis (Marfella et al., 2000) (Chen et al., 2004).

In the present study there was significant difference among different HbA1c groups as regard, number of diseased coronary vessels with higher number of three vessel disease in group (3) with statistically significant positive correlation between HbA1c and number of diseased vessel (r=3.693, p=0.000). This was concordant with previous studies (Cakmak et al., 2008) (Kassian et al., 2012). This goes with the fact that HbA1c increase of one percent is associated with 2.8 fold increase in CAD and in severity of coronary artery lesions, this was explained by the fact that insulin resistance in hyperglycemia promote molecular mechanism by Advanced Glycation End products (AGEs) which are intimately involved in the pathophysiology of cardiovascular disease by stimulating inflammation, contributing to atheroma formation modulating vascular stiffness and the disturbed endothelial function by reduction nitric oxide release, increased vascular smooth muscle proliferation (Prasad et al., 2012). beyond high risk profile of those patients, it is worth mentioning that even HbA1c value in normal range is associated with presence and severity of CAD (Ashraf et al., 2013).

On the contrary, this was discordant with (Ertem et al., 2013) who found no significant difference between HbA1c level and severity of CAD. This discrepancy was due to that he used Gensini score for assessment of the severity CAD in his study and non-diabetic were only included in his study.

In the present study there was significant difference among different HbA1c groups as regard lesion type (A, B, C). This was concordant with (Kassian et al., 2012) who found highly significant difference among HbA1c groups as regard lesion type C. This goes with the fact that diabetes is associated with more extensive coronary artery lesion, more complex lesion more diffuse exousiousity in the proximal segment, extreme angulations and total occlusion (Ryan et al., 1988).

In the present study there was significant difference among different HbA1c groups as regard TIMI flow grades in patients who had undergone 1ry PCI, with higher percentage of TIMI 3 in group (1) and significant higher percentage of TIMI 1 in favor of group (3), this finding goes with the fact that hyperglycemia is associated with higher rate of TIMI 0/1 and lower rate of complete revascularization TIMI 3. This was concordant with (Planner et al., 2013), this was explained by the fact that hyperglycemia adversely affect platelets function, endothelial function, promote inflammation and result in procoagulable condition, it is worth mentioning that hyperglycemia per se in STEMI lead to impaired coronary flow on presentation and after primary PCI (Bobbette et al., 2011). This goes with our finding that TIMI 3 complete revascularization is higher in group (1) the least level of HbA1c, and TIMI 1 flow has statistically significant difference between group (1) and (3) with higher percentage in favor of group (3) the highest level of HbA1c, beyond that patients with higher HbA1c on admission have larger myocardial infarction and less frequently have open infarct artery.

In the present study we assess HbA1c level on the short-term outcome (six months) to detect major adverse cardiac event as mortality, heart failure and reinfarction. In the present study there was significant difference among different HbA1c groups as regard adverse cardiac events, this was concordant with previous studies (Cakmak et al., 2008) (Kassian et al., 2012). This goes with the fact that hyperglycemia is associated with large infarct size, more hemodynamic compromise, congestive heart failure, cardiogenic shock and mortality, beyond the fact that diabetic patients with poor glycemic control are at two-fold more risk of developing MACE, while good controlled diabetics showed lower rates comparable to non-diabetics.

In the present study there was higher percentage of mortality in favor of group (3). This was concordant with (Cakmak et al., 2008) this goes with the fact that higher HbA1c level at admission was associated with higher baseline characteristics, larger infarct, more extensive coronary artery lesion, lower STR, higher percentage of TIMI 1 flow, lower rate of complete revascularization TIMI 3 flow.

Regarding diabetes mellitus and HbA1c, both predict adverse outcome in the present study. This was concordant with (Cakmak et al., 2008), this goes with the fact that hyperglycemia is associated with larger infarct size, lower successful response to reperfusion and high-risk profile. On the contrary, this was discordant with (Lazzerietal., 2012), this discrepancy was due to that non-diabetic patients were only included in his study.
The present study shows that there was significant difference between both types of reperfusion as regard complete and partial STR in favor of primary PCI, this was concordant with (Sejersten et al., 2009), this goes with the fact that superiority of primary percutaneous coronary intervention over fibrinolysis, if the door-to-balloon is completed in a timely fashion because TIMI 3 flow is achieved more in primary PCI patients, but we found no significant difference between both types of reperfusion regarding biochemical data, severity of CAD, outcome of adverse cardiac events. This was concordant with three previous studies (Ribichini et al., 1998) (Mehta et al., 2004) (Zijsstra et al., 1993), this was explained in our study by small sample size, which make our study not powered to detect difference between two types of reperfusion beyond short term follow up period and random selection cases according to capability of our primary PCI center.

Conclusion: -

The present study shows that admission higher HbA1c level in patients presented by acute STEMI is associated with more severe CAD, lower ST segment resolution, lower rate of complete revascularization TIMI 3 and higher incidence of mortality.

Higher HbA1c level should be considered for risk stratification of patients presented by acute STEMI who are amenable to primary PCI

References: -